Lineage Cell Therapeutics Files Proxy Materials
Ticker: LCTX · Form: DEFA14A · Filed: Apr 29, 2026 · CIK: 0000876343
| Field | Detail |
|---|---|
| Company | Lineage Cell Therapeutics, Inc. (LCTX) |
| Form Type | DEFA14A |
| Filed Date | Apr 29, 2026 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-filing, shareholder-materials
Related Tickers: LCTX
TL;DR
LCTX filed proxy docs 4/29/26 - shareholder votes coming up.
AI Summary
Lineage Cell Therapeutics, Inc. filed a DEFA14A on April 29, 2026, related to additional definitive proxy soliciting materials. The filing includes proxy materials and graphic elements, with the company's principal executive offices located at 2173 Salk Avenue, Suite 200, Carlsbad, CA 92008.
Why It Matters
This filing indicates that Lineage Cell Therapeutics is engaging in proxy solicitations, which are crucial for shareholder voting on corporate matters.
Risk Assessment
Risk Level: low — This is a routine proxy filing and does not contain information about significant financial changes or strategic shifts.
Key Players & Entities
- Lineage Cell Therapeutics, Inc. (company) — Filer of the DEFA14A
- 0000876343 (company) — CIK number for Lineage Cell Therapeutics, Inc.
- 2026-04-29 (date) — Filing date of the DEFA14A
- 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 (company) — Mailing and Business Address for Lineage Cell Therapeutics, Inc.
FAQ
What type of filing is this DEFA14A for Lineage Cell Therapeutics, Inc.?
This DEFA14A filing is for additional definitive proxy soliciting materials and Rule 14(a)(12) material.
When was this DEFA14A filing accepted by the SEC?
The filing was accepted on 2026-04-29 at 16:15:01.
What is the CIK number for Lineage Cell Therapeutics, Inc.?
The CIK number for Lineage Cell Therapeutics, Inc. is 0000876343.
What is the business address of Lineage Cell Therapeutics, Inc.?
The business address is 2173 Salk Avenue, Suite 200, Carlsbad, CA 92008.
What SIC code is associated with Lineage Cell Therapeutics, Inc.?
The SIC code is 2836 for Biological Products, (No Diagnostic Substances).
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 29, 2026 regarding Lineage Cell Therapeutics, Inc. (LCTX).